[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-complications":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,82,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100463051","cardiac-outcomes-with-near-complete-estrogen-deprivation-100463051",false,"NCT05309655","Cardiac Outcomes With Near-Complete Estrogen Deprivation","The Cardiac Outcomes With Near-Complete Estrogen Deprivation (CROWN) Study","CROWN","Inclusion Criteria\n\n* Women age ≤55 who were premenopausal at the time of breast cancer diagnosis; (Premenopausal is defined as per NCCN criteria).\n* Planned breast cancer treatment with NCED (near-complete estrogen deprivation) therapy that includes aromatase inhibitor therapy (or SERD) with medically or surgically induced menopause within three (3) months of initiating NCED (HR-positive tumor) or, for the cohorts not receiving NCED therapy, within three (3) months of planned chemotherapy, surgery or radiation. Index date for three months is defined as final date of treatment with chemotherapy, surgery or radiation which ever happens last (HR-negative tumor). Treatment with a Gonadotropin Releasing Hormone (GnRH) agonist for fertility preservation during chemotherapy is allowed and is not considered part of the NCED antineoplastic therapy.\n* Women with human epidermal growth factor-2 (HER2) negative and women with human epidermal growth factor-2 (HER2) positive breast cancer are eligible.\n* Treatment with CDK-inhibitor, PARP inhibitor immunotherapy or biologic (non-chemotherapy) agent as part of anti-neoplastic treatment plan is allowed. These agents are not considered chemotherapy.\n* Treatment with selective-estrogen receptor degrader (SERD) rather than aromatase inhibitor is allowed.\n* Diagnosed with Stage I-III breast cancer.\n* ECOG performance status of 0-2\n* Patients with concurrent malignancies are eligible as long as therapies and disease course for these are reasonably expected to not impact cardiovascular function. (Examples of eligible malignancies include: papillary\u002Ffollicular thyroid cancer, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ and early stage cervical cancers, etc.).\n* Patients with prior COVID-19 are eligible if they have recovered from the illness and are free of COVID-related symptoms other than allowable persistent symptoms: loss of taste and smell and\u002For grade 1 fatigue.\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).\n* The study will allow up to 30% of patients with MRI non-compatible breast expanders recognizing that baseline CMR will be outside of imaging window. Note: Registration of these participants will require study PI approval (Dr. Jordan or Dr. Thomas).\n\nExclusion Criteria:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to adenosine\n* Active wheezing.\n* Those with contraindications for MRI such as ferromagnetic cerebral aneurysm clips or other intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices, or some breast expanders.\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study. Because some methods of birth control are not 100% reliable, a pregnancy test is required, unless the patient has undergone either a bilateral oophorectomy, hysterectomy or both.\n* Coronary revascularization in the past 6 months or known severe multi-vessel coronary artery disease previously determined to be not amendable to mechanical intervention.\n* Ongoing, unrelieved symptoms thought to represent cardiac ischemia and requiring immediate cardiac catheterization\n* Allergy or prior sensitivity to gadolinium or other contrasting agents or their excipients.\n* Men with breast cancer.\n* Known chronic renal insufficiency or chronic electrolyte abnormalities as determined by the treating physician.","FEMALE","18 Years","55 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this research study is to understand what effect near complete estrogen deprivation (NCED) therapy has on the heart in breast cancer patients. Investigators want to understand if NCED changes how the heart works.",[28,29,30],"Breast Cancer","Triple Negative Breast Cancer","Cardiovascular Complications","RECRUITING","2026-03-13",{"date":34,"type":35},"2026-03-16","ACTUAL",{"date":37,"type":35},"2022-09-02",{"date":39,"type":22},"2028-12-01",{"name":41,"class":42},"Duke University","OTHER",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100562875","the-incidence-of-pulmonary-cardiovascular-and-renal-system-non-communicable-complications-associated-with-the-post-acute-phase-of-the-infection-by-covid-19-100562875","NCT06608849","The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19","A Non-interventional, Prospective, Cross-sectional Study of the Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Sars-Cov-2","POINT","Inclusion Criteria:\n\nGroup A (comparators)\n\n1. Adults (18 years or more) of both genders\n2. Negative history of acute COVID-19\n\nGroup B (patients with ΝΟ dysfunction)\n\n1. Adults (18 years or more) of both genders\n2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply\n3. Absence of any current overt organ dysfunction\n4. Absence of signs of any organ dysfunction during acute COVID-19\n\nGroup C (patients with dysfunctions)\n\n1. Adults (18 years or more) of both genders\n2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply\n3. Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19\n\nExclusion Criteria:\n\nGroup A (comparators)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Failure to thrive according to the attending physicians\n3. Pregnancy or lactation\n\nGroup B (patients with ΝΟ dysfunction)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Failure to thrive according to the attending physicians\n3. Pregnancy or lactation\n\nGroup C (patients with dysfunctions)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Medical history of any of:\n\n   * stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria\n   * pulmonary fibrosis or pulmonary hypertension\n   * stage IV solid tumour malignancy under chemotherapy or radiotherapy\n   * systemic sclerosis\n   * congestive heart failure\n   * stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19\n3. Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation",true,"ALL",{"count":55,"type":22},345,"OBSERVATIONAL","More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19.\n\nThe overall concept underpinning \"POINT\" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous, current, and future SARS-CoV-2 variants in vaccinated and unvaccinated people, and NCDs, ii) identify robust biomarkers and build predictive tools that help early identification and management of risk of NCDs, and iii) develop guidelines and recommendations for all parts of the healthcare value chain, allowing best prevention and care acknowledging vulnerability. The investigators will focus on the NCDs affecting pulmonary, cardiovascular and renal systems.",[59,30,60,61],"Pulmonary Complications","Renal Complications","COVID-19",[63,64,65,66,67,68,69,70,71],"Covid-19","SARS-CoV-2","Pulmonary complications","Cardiovascular complications","Renal complications","Post-acute phase","Non communicable diseases","Biomarkers","Prevention","2025-11-14",{"date":74,"type":35},"2025-11-17",{"date":76,"type":35},"2024-12-10",{"date":78,"type":22},"2027-11-04",{"name":80,"class":42},"Hellenic Institute for the Study of Sepsis",6,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100600971","an-epidemiological-and-long-term-endpoint-registry-study-on-disease-syndrome-correlation-patterns-in-comorbid-population-with-diabetes-and-ischemic-cardio-cerebrovascular-disease-100600971","NCT07104422","An Epidemiological and Long-Term Endpoint Registry Study on Disease-Syndrome Correlation Patterns in Comorbid Population With Diabetes and Ischemic Cardio-Cerebrovascular Disease","Diabetes","Inclusion Criteria:\n\n* Aged ≥ 18 years Diagnosed with comorbidities relevant to \"toxin-damaged collaterals\" theory (e.g., type 2 diabetes mellitus with cardiovascular\u002Fcerebrovascular disease).\n\nVoluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n* Acute infectious diseases, malignant tumors, or autoimmune disorders. Mental illness or cognitive impairment affecting symptom assessment.",{"count":90,"type":22},12000,"Explore the characteristics of TCM syndrome elements and distribution patterns of syndrome types in comorbid populations; Screen for \"high-risk syndrome patterns\" and frequently co-occurring complex syndromes; Identify characteristic syndrome patterns at key stages: acute phase, recovery phase, and upon occurrence of endpoint events; Investigate the temporal evolution of TCM syndrome patterns and the disease-syndrome correlation patterns in comorbid patients.",[93,30],"Type 2 Diabetes Mellitus (T2DM)",[95,96,97,98],"Diabetes comorbidities","Cardiovascular-cerebrovascular diseases","Real-world registry study","Disease-syndrome correlation","NOT_YET_RECRUITING","2025-07-29",{"date":102,"type":35},"2025-08-05",{"date":104,"type":22},"2025-08-15",{"date":106,"type":22},"2028-07-30",{"name":108,"class":42},"Guangzhou University of Traditional Chinese Medicine",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":53,"minAge":116,"maxAge":18,"enrollmentInfo":117,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100500017","vascular-complications-in-children-from-t1d-diagnosis-100500017","NCT05790785","Vascular Complications in Children From T1D Diagnosis","Understanding Vascular Complications in Children From Type 1 Diabetes Diagnosis","Inclusion Criteria\n\n1. Between the ages of 8-18 years\n2. Within 14 weeks of type 1 diabetes diagnosis\n3. Ability and willingness to undergo non-invasive arterial stiffness assessment for 1hr and willingness to wear the 24-h automated blood pressure monitoring (ABPM) device.\n\nExclusion Criteria\n\nChildren will be ineligible to participate in the study if they meet any of the following:\n\n1. Other cardiometabolic or endocrine diseases diagnosis (type 2 diabetes; familial disorders of cholesterol metabolism; lupus)\n2. Other genetic syndromes (Down Syndrome; Prader-Willi)\n3. Eating disorder diagnosis\n4. Transgender children taking hormone blockers or exogenous sex steroids\n5. Currently treated with medications known to affect metabolism (e.g. glucocorticoids, antipsychotics).","8 Years",{"count":118,"type":22},150,"Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.",[121,30,122,123],"Type 1 Diabetes","Child","Adolescent",[125,126,127,128,70,129,130],"Type 1 diabetes","Children","Arterial stiffness","Body composition","Nutrition","Blood pressure","2025-04-29",{"date":133,"type":35},"2025-05-02",{"date":135,"type":35},"2024-03-25",{"date":137,"type":22},"2027-09-30",{"name":139,"class":42},"University of British Columbia",1]